KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Revenue (2016 - 2025)

BeOne Medicines (ONC) has disclosed Revenue for 11 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 32.84% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 billion, a 40.23% increase, with the full-year FY2025 number at $5.3 billion, up 40.23% from a year prior.
  • Revenue was $1.5 billion for Q4 2025 at BeOne Medicines, up from $1.4 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.5 billion in Q4 2025 to a low of $150.0 million in Q2 2021.
  • A 5-year average of $710.2 million and a median of $620.1 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 1063.82% in 2021, then crashed 49.39% in 2022.
  • BeOne Medicines' Revenue stood at $214.0 million in 2021, then surged by 77.63% to $380.1 million in 2022, then surged by 66.91% to $634.4 million in 2023, then surged by 77.78% to $1.1 billion in 2024, then skyrocketed by 32.84% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Revenue are $1.5 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).